American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors

被引:0
|
作者
Baskaran, Archit B. [1 ]
Kumthekar, Priya [2 ,3 ]
Heimberger, Amy B. [3 ,4 ]
Lukas, Rimas, V [2 ,3 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA
[3] Northwestern Univ, Lou & Jean Malnati Brain Tumor Inst, Chicago, IL 60611 USA
[4] Northwestern Univ, Dept Neurosurg, Chicago, IL 60611 USA
关键词
brain metastases; craniopharyngioma; glioblastoma; leptomeningeal metastases; meeting report; neuro-oncology; TEMOZOLOMIDE; TRIAL; COMBINATION; EFFICACY; CELLS; PLUS;
D O I
10.2217/fon-2021-0955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this report, select key studies presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting are reviewed. Two major phase III randomized controlled trials were presented at the meeting: GEINO 1401 and EORTC 1709/CCTG CE.8. Both are reviewed in this report. Moreover, important phase II trials, including Alliance A0716701, and key phase I trials are included. All trials presented cover important advances in the understanding of primary brain tumor management. In addition, case series papers, trials in progress and select work on exploratory CSF biomarkers are reviewed. Altogether, research presented at ASCO 2021 highlights important advances in neuro-oncologic topics that may inform future research and practice.
引用
收藏
页码:4425 / 4429
页数:5
相关论文
共 50 条